EGFR and head and neck squamous cell carcinoma: The complex crosstalk in cellular control networks opens new avenues for combination treatment protocols involving EGFR inhibitors and possibly also other targeted agents. There are abundant possibilities for bringing c-MET inhibitors to the clinic as a targeted therapeutic drugs fostering checks through metabolic signaling, tumor-microenvironment and immune modulations in HNSCC.